INHIBRX INC (INBX)
US45720L1070 - Common Stock
Inhibrx Becomes Oversold (INBX)
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates WRK, TGAN, ANSS, INBX
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates TAST, MDC, INBX
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates MDC, INBX, KAMN, HAYN
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates INBX, BATL, KAMN
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Inhibrx reports Q4 results (NASDAQ:INBX)
Inhibrx reports a net loss of $93.6M in Q4 2023. Cash and cash equivalents stand at $277.9M.
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong...
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AMAM, JNPR, INBX, RYZB
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates INBX, KAMN, BATL
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Kuehn Law Encourages DOC, BATL, KAMN, and INBX Investors to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
Noteworthy Tuesday Option Activity: JPM, INBX, ROG
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates INBX, SP, WAVD, CATC
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Unitholder Alert: Ademi LLP investigates whether Inhibrx, Inc. has obtained a Fair Price in its transaction with Sanofi
/PRNewswire/ -- Ademi LLP is investigating Inhibrx (Nasdaq: INBX) in connection with its transaction with Sanofi. Click here to learn how to join...
Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx
The company is buying Inhibrx, which is working on a treatment for alpha-1 antitrypsin deficiency.
INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholders
Sanofi to acquire Inhibrx rare disease asset in $2.2B deal (NASDAQ:SNY)
Sanofi strengthens its rare disease portfolio through the acquisition of Inhibrx's assets, including a potential best-in-class rare disease asset, for...
Sanofi to Buy Biotech Firm for $2.2 Billion in Innovation Push
Sanofi will buy Inhibrx Inc. for as much as $2.2 billion, giving the French pharmaceutical firm ownership of a potential therapy for an inherited genetic condition called Alpha-1 Antitrypsin Deficiency.
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") and Sanofi (Nasdaq: SNY) ("Sanofi") today announced that the companies have entered...
Interesting INBX Put And Call Options For March 15th
Notable Friday Option Activity: MSTR, COIN, INBX
First Week of February 2024 Options Trading For Inhibrx (INBX)
Commit To Buy Inhibrx At $22.50, Earn 33% Annualized Using Options
Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical trials and a...
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare...
Inhibrx Becomes Oversold (INBX)
Inhibrx Announces Participation in Upcoming Scientific Conferences
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare...
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare...
First Week of INBX November 17th Options Trading
Inhibrx up 1.2% on $200M private placement (NASDAQ:INBX)
linical-stage biopharmaceutical company Inhibrx (INBX) entered into a securities purchase agreement for a private placement
Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical trials and a...